Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a ...

Novel capsid technology to enable convenient delivery in the doctor's office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease Ikarovec Ltd, which is devel ...

Contaminated drinking water in Indore, India, was linked to 10 deaths and more than 270 hospitalizations, according to ...

A custom 30 G needle with a closed tip and side port shows equivalent performance to standard needles for anti-VEGF delivery.

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Ophthalmologists recognized at the ‘Surgical Strike 360’ conference in Chennai, showcasing innovative techniques and ...

Shares in biopharmaceutical group Outlook Therapeutics ($OTLK) collapsed in pre-market trading after the U.S. Food and Drug ...

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.

Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...